|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100050448 |
|
最近更新日期: Date of Last Refreshed on: |
2021-08-27 15:06:37 |
|
注册时间: Date of Registration: |
2021-08-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
TICL与TG-LASIK矫正散光的矢量分析 |
|
Public title: |
Vector analysis of toric implantable collamer lens implantation and corneal topography guided FS-LASIK for astigmatism correction |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
TICL与TG-LASIK矫正散光的矢量分析 |
|
Scientific title: |
Vector analysis of toric implantable collamer lens implantation and corneal topography guided FS-LASIK for astigmatism correction |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
魏润菁 |
研究负责人: |
魏润菁 |
|
Applicant: |
WeiRunjing |
Study leader: |
WeiRunjing |
|
申请注册联系人电话: Applicant telephone: |
18062073151 |
研究负责人电话:
Study leader's |
18062073151 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wrj1220@163.com |
研究负责人电子邮件: Study leader's E-mail: |
wrj1220@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
武汉市洪山区民族大道159号 |
研究负责人通讯地址: |
武汉市洪山区民族大道159号 |
|
Applicant address: |
No.159 Minzu Avenue, Hongshan District, Wuhan City |
Study leader's address: |
No.159 Minzu Avenue, Hongshan District, Wuhan City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
武汉爱尔眼科洪山医院 |
||
|
Applicant's institution: |
Wuhan Aier Hongshan Eye Hosptal |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
HS2021IRBKY09 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
武汉爱尔眼科洪山医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Wuhan Aier Hongshan Eye Hosptal |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-03-05 00:00:00 | ||
|
伦理委员会联系人: |
陈茜 |
||
|
Contact Name of the ethic committee: |
ChenQian |
||
|
伦理委员会联系地址: |
武汉市洪山区民族大道159号 |
||
|
Contact Address of the ethic committee: |
No.159 Minzu Avenue, Hongshan District, Wuhan City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
武汉爱尔眼科洪山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Wuhan Aier Hongshan Eye Hosptal |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
武汉市洪山区民族大道159号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.159 Minzu Avenue, Hongshan District, Wuhan City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
武汉爱尔眼科洪山医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
Wuhan Aier Hongshan Eye Hosptal |
||||||||||||||||||||||
|
研究疾病: |
屈光不正 |
||||||||||||||||||||||
|
Target disease: |
Ametropia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
有晶状体眼后房型散光型人工晶状体(TICL)因其优越的术后视觉质量,被越来越多人接受。但在TICL植入的过程中由于无法精准定位,视轴和晶状体中心可能不同,因而会产生误差角;且TICL的治疗梯度是0.5D,可能会降低散光的矫正效果。Alpins矢量法可以量化评估术后散光与轴向的偏差,分析TICL矫正散光的精确性。在角膜屈光手术中TG-LASIK(角膜地形图引导个性化飞秒激光辅助的原位角膜磨镶术)的虹膜跟踪定位技术使其在散光的矫正方面更加优越。目前TICL和TG-LASIK都是矫正近视散光的主流手术方式。本研究通过矢量分析,量化TICL和TG-LASIK对散光的矫正,对两种手术方式术前术后的散光进行分析比较,来探讨TICL和TG-LASIK在散光矫正方面的精确性,对手术方式的选择提供临床指导。 |
||||||||||||||||||||||
|
Objectives of Study: |
Toric implantable collamer lens (TICL) has been accepted by more and more people because of its superior visual quality after operation. However, in the process of TICL implantation, due to the inability to locate accurately, the visual axis and the center of the lens may be different, which will lead to error angle; And the therapeutic gradient of TICL is 0.5D, which may reduce the correction effect of astigmatism. Alpins vector method can quantitatively evaluate the deviation between astigmatism and axial direction after operation, and analyze the accuracy of TICL in correcting astigmatism. In corneal refractive surgery, the corneal topography guided FS-LASIK (TG-LASIK) makes it superior in astigmatism correction. At present, TICL and TG-LASIK are the mainstream surgical methods to correct myopia and astigmatism. Through vector analysis, this study quantifies the correction of astigmatism by TICL and TG-LASIK, and analyzes and compares the astigmatism before and after the two surgical methods, so as to explore the accuracy of TICL and TG-LASIK in astigmatism correction and provide clinical guidance for the choice of surgical methods. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①年龄18~40周岁;②屈光度相对稳定,即连续2年每年屈光度数变化 <0.50D;③散光度数高于-1.00D,低于-6.00D;④瞳孔直径在6mm以内;⑤角膜曲率在40D~46D之间;⑥角膜最薄点厚度符合手术条件;⑦眼压在10~21mmHg之间;⑧停戴软性隐形眼镜1周以上,停戴RGP1月以上,停戴角膜塑形镜3月以上;⑨有良好的依从性,能够遵医嘱并坚持定期复查。 |
||||||||||||||||||||||
|
Inclusion criteria |
① Age 18 ~ 40 years old; ② The refractive power is relatively stable, that is, the annual refractive power change is less than 0.50D for two consecutive years; ③ Astigmatism degree is higher than -1.00D and lower than-6.00D; ④ Pupil diameter is less than 6mm; ⑤ Corneal curvature is between 40D and 46D. ⑥ The thickness of the thinnest point of cornea meets the operation conditions. ⑦ IOP is between 10~21mmHg; ⑧ Stop wearing soft contact lenses for more than 1 week, RGP for more than 1 month, and OrthoK for more than 3 months; ⑨Has good compliance, can follow the doctor's advice and insist on regular review. |
||||||||||||||||||||||
|
排除标准: |
①屈光度数超过适应证范围;②角膜地形图检查结果不可信、重复性差;③术中不能获得良好的眼球跟踪定位;④预计 TG-LASIK 术后角膜最薄点厚度角膜瓣下不足 250 μm、角膜表层屈光手术后角膜最薄点厚 度不足 360 μm;⑤圆锥角膜或其他角膜扩张性变化处于未稳定状态;⑥活动性眼部病变或感染; ⑦明显影响视力的眼部疾病; ⑧严重焦虑、抑郁等心理、精神疾病;⑨无法配合检查和手术的疾病,如癫痫、癔症等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
① The refractive power exceeds the indication range; ② The results of corneal topography examination are unreliable and poor in repeatability; ③ Good eye tracking and positioning can not be obtained during operation; ④ It is estimated that the thickness of the thinnest point of cornea after TG-LASIK is less than 250 μm under corneal flap and less than 360 μm after corneal surface refractive surgery. ⑤ The dilative changes of keratoconus or other corneas are in unstable state; ⑥ Active eye diseases or infections; ⑦ Eye diseases that significantly affect vision; ⑧ Serious anxiety, depression and other psychological and mental diseases; ⑨Can't cooperate with examination and surgery diseases, such as epilepsy, hysteria, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-09-15 00:00:00至 To 2023-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-09-15 00:00:00 至 To 2022-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
在研究期间内自主来武汉爱尔眼科洪山医院就诊的患者中,由我院从事屈光手术工作16年的陈茜副主任医师根据各手术纳入标准征募研究对象. |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
During the study period, among the patients who visited the refractive surgery department of Wuhan Hongshan Aier Eye Hospital, Deputy Director Qian Chen, who has been engaged in refractive surgery clinical work for 16 years, recruited the study subjects according to the inclusion criteria. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |